Life Sciences

  • July 06, 2026

    The Funniest Moments Of The Supreme Court's Term

    When one of the U.S. Supreme Court's most talkative members suddenly struggled to speak, the atmosphere at oral arguments grew increasingly anxious — until the justice deadpanned that it was an advocate's golden opportunity to avoid a grilling.

  • July 06, 2026

    Diagnostic Co.'s Oversight Reforms Deal Gets Final OK

    A California federal judge has given final approval to a deal ending shareholder derivative claims that diagnostics company CareDx's executives and directors damaged the company by concealing its scheme to inflate its testing services revenue.

  • July 06, 2026

    Illumina Looks To Duck DNA Rival's Renewed Antitrust Case

    Illumina told a California federal court an antitrust case from DNA sequencing startup Element Biosciences should be tossed for good because it continues to attack legitimate discounts that do nothing to block competition.

  • July 06, 2026

    Edwards Lifesciences Investors Seek 1st OK For $39M Deal

    Investors of Edwards Lifesciences Corp. have asked a California federal judge to grant the first green light to a $39 million settlement the parties reached to resolve claims that the medical technology company and its top brass made misleading statements about the growth of its leading artificial heart valve product.

  • July 06, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week handled disputes involving arbitration, corporate control, advancement rights, freeze-out mergers and insolvent company wind-downs.

  • July 02, 2026

    The Firms That Won Big At The Supreme Court

    This U.S. Supreme Court term featured high-stakes oral arguments on issues including presidential power, immigration and voting regulations. Here's a look at the law firms that argued the most cases and how they fared.

  • July 02, 2026

    The Sharpest Dissents From The Supreme Court Term

    The sharpest dissents this term often involved the president, and pitted conservative and liberal justices against each other on core constitutional issues and questions about the limits to executive power, with nearly a quarter of cases being decided squarely along ideological lines.

  • July 02, 2026

    The Year Donald Trump Won Big At The High Court

    The Supreme Court's conservative supermajority and President Donald Trump largely aligned this year on issues of executive power, resulting in a series of decisions that significantly expanded presidential authority.

  • July 02, 2026

    Pharma CEO, Daughter To Pay $2M In SEC Stock Fraud Case

    The Texas-based CEO of a purported pharmaceutical company and his daughter will pay nearly $2 million to end the U.S. Securities and Exchange Commission's claims accusing them and several others of participating in a $92 million penny stock fraud scheme.

  • July 02, 2026

    Amgen, Sanofi Team Up To Urge En Banc Antibody IP Review

    Rival pharmaceutical companies that squared off at the U.S. Supreme Court over antibody patents have jointly asked the full Federal Circuit to review an unrelated panel decision reviving migraine drug antibody patents.

  • July 02, 2026

    DOJ Has 'Negligible Interest' In Trans Patient Info, Judge Says

    A California federal judge on Thursday blocked the U.S. Department of Justice from trying to identify individuals who received gender-affirming care from a Stanford Medicine hospital as minors, finding grand jury subpoena demands seeking that information likely violated the Fifth Amendment.

  • July 02, 2026

    Cox, Hikma Rulings Set Stage For Trademark Liability Fights

    After the U.S. Supreme Court narrowed paths to secondary liability in copyright and patent cases this term, trademark law stands apart with an older, potentially broader rule for when intermediaries can be held liable for another party's infringement.

  • July 02, 2026

    Insulet Investor Says Device Production Issues Tanked Stock

    Insulet Corp. artificially inflated the price of its shares by not disclosing to investors issues with its manufacturing procedures, leading the insulin-delivery device company to initiate medical device corrections and take a hit to its share price, according to a shareholder suit filed Thursday in Massachusetts federal court.

  • July 02, 2026

    Fed. Circ. Won't Restore Doctor's Intubation Patent Suit

    The Federal Circuit on Thursday declined to give a doctor another chance to pursue a suit against medical supplies company Teleflex Medical Inc. alleging infringement of a patent covering a laryngoscope used to intubate a patient, affirming the claim construction of a lower court.

  • July 02, 2026

    Sinclair Convinces Ga. Panel To Sink Doctor's Defamation Suit

    A Georgia appellate panel sided with media conglomerate Sinclair Broadcast Group and a nurse who was interviewed about alleged forced sterilizations of U.S. Immigration and Customs Enforcement detainees, saying a trial court erred by letting a doctor's defamation suit proceed.  

  • July 02, 2026

    Chubb, Lloyd's Units Seek Further Win Against Opioid Suits

    Chubb, Liberty Mutual and Lloyd's of London units and other insurers urged a Pennsylvania federal court to find that they don't owe any additional coverage to bankrupt pharmaceutical company Endo International for the remainder of third-party payor opioid lawsuits filed against Endo during its 2017-2018 policy period.

  • July 02, 2026

    Senate Dems Say OMB Rule Would Politicize Federal Grants

    The entire Senate Democratic Caucus is urging the Office of Management and Budget to abandon a new proposed rule that they say will politicize the federal grants process.

  • July 02, 2026

    United Therapeutics Buys Thymmune For Up To $300M

    Biotechnology firm United Therapeutics Corp. on Thursday revealed that it has agreed to buy a preclinical-stage biotech company focused on thymic cell therapies in a deal worth up to $300 million.

  • July 02, 2026

    Skadden Adds Mass Torts Litigator As Partner In Chicago

    Skadden Arps Slate Meagher & Flom LLP has grown its mass torts litigation offerings in Chicago with the addition of a Goldman Ismail Tomaselli Brennan & Baum LLP attorney, the firm said.

  • July 02, 2026

    Breaking Down The Vote: The High Court Term In Review

    The U.S. Supreme Court's stark ideological divisions were on full display this term, particularly as it issued long-awaited rulings in the last few days of June. Here, Law360 dives into the numbers behind this court term.

  • July 02, 2026

    CMS Proposes Cut To Hospitals' 340B Drug Reimbursements

    Federal health officials on Thursday proposed a Medicare spending plan that would slash reimbursement for hospitals participating in the 340B drug pricing program and reduce how much all hospitals receive for certain imaging tests.

  • July 02, 2026

    Product Liability Q2 Regulatory Roundup

    This spring and early summer saw the EPA setting its sights on "forever chemicals," approving some of them for use in pesticides and clawing back limits on their presence in drinking water. The former top FDA official is now out, and several nominees are waiting to fill gaps at the Consumer Product Safety Commission. 

  • July 01, 2026

    Big Pharma Cos. Want 340B Drug Price FCA Suit Tossed

    Four major pharmaceutical companies Wednesday urged a California federal court to toss False Claims Act allegations revived by the Ninth Circuit claiming they filed false ceiling prices for drugs and overcharged entities covered by a federal discount program, saying the suit is precluded by the FCA's public disclosure bar.

  • July 01, 2026

    3 Federal Circuit Clashes To Watch In July

    A patent owner's effort to undo a Texas jury verdict clearing Samsung of infringing a wireless patent and an appeal of a ruling that Dartmouth College and a supplement maker owe $9 million for filing an "unreasonable" vitamin patent suit are among the cases the Federal Circuit will hear this month.

  • July 01, 2026

    Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says

    A New York federal magistrate judge has recommended awarding $68 million to biopharmaceutical company Gilead Sciences Inc. from a group of companies it accused of producing counterfeit HIV drugs that never answered the allegations.

Expert Analysis

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.